BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 8758211)

  • 1. Cadherin expression in melanocytic naevi and malignant melanomas.
    Cowley GP; Smith ME
    J Pathol; 1996 Jun; 179(2):183-7. PubMed ID: 8758211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E-cadherin/catenin complex in benign and malignant melanocytic lesions.
    Silye R; Karayiannakis AJ; Syrigos KN; Poole S; van Noorden S; Batchelor W; Regele H; Sega W; Boesmueller H; Krausz T; Pignatelli M
    J Pathol; 1998 Dec; 186(4):350-5. PubMed ID: 10209482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
    Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
    J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro-anatomy related antigen expression in melanocytic lesions.
    Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
    J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of neurotrophins and their receptors in pigment cell lesions of the skin.
    Innominato PF; Libbrecht L; van den Oord JJ
    J Pathol; 2001 May; 194(1):95-100. PubMed ID: 11329147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ expression patterns of melanoma-inhibiting activity (MIA) in melanomas and breast cancers.
    Bosserhoff AK; Moser M; Hein R; Landthaler M; Buettner R
    J Pathol; 1999 Mar; 187(4):446-54. PubMed ID: 10398105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression patterns of S100 proteins in melanocytes and melanocytic lesions.
    Petersson S; Shubbar E; Enerbäck L; Enerbäck C
    Melanoma Res; 2009 Aug; 19(4):215-25. PubMed ID: 19521263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours.
    Sanders DS; Blessing K; Hassan GA; Bruton R; Marsden JR; Jankowski J
    Mol Pathol; 1999 Jun; 52(3):151-7. PubMed ID: 10621837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas.
    Gong J; Chen N; Zhou Q; Yang B; Wang Y; Wang X
    J Clin Pathol; 2005 Oct; 58(10):1081-5. PubMed ID: 16189155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
    Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
    Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
    Krengel S; Grotelüschen F; Bartsch S; Tronnier M
    J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of intercellular adhesion molecule-1 (ICAM-1) in benign naevi and malignant melanomas.
    Hansen NL; Ralfkiaer E; Hou-Jensen K; Thomsen K; Drzewiecki KT; Rothlein R; Vejlsgaard GL
    Acta Derm Venereol; 1991; 71(1):48-51. PubMed ID: 1676215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic beta-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis?
    De Panfilis G; Ferrari D; Santoro S; Ricci R; Lombardi M; Pedrazzi G; Pepe C; Cortelazzi C; Santini M
    Br J Dermatol; 2009 Mar; 160(3):600-8. PubMed ID: 19183173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma.
    Kuphal S; Bosserhoff AK
    Oncogene; 2006 Jan; 25(2):248-59. PubMed ID: 16132038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
    Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
    Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
    Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
    Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.